Replies to post #321655 on Avid Bioservices Inc (CDMO)

[asmarterwookie]

ALSO, the new human analogue, "microspheres", are being used by investigators.

http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3060

wook

[revenue_monster]

but the Brekken comments were prior to sunrise being unblinded and referenced in the lab.

[eb0783]

Not only are they humans, but we have known for over 10 years that Bavi MAY work better in humans than in animals. This is not new but neither is the dirge of "it only works in animals." Someone is behind times and I don't think it was Dr. PHILIP THORPE or is Dr. Brekken.

FROM 2003:
8-2003 NIAID LASSA Grant: “The phospholipids that they recognize have the same structure and cellular distribution in different mammalian species, simplifying the transition from experimental animals into humans.”

FROM 2005:
10-24-05: Thorpe, in response to humans vs. animals question: “All animal species have the same regulation. What I haven’t explained is that PS is one in the same molecule in humans, mice, and all higher species. As far as we know, there is no difference in the regulation of these molecules between humans and other species. If you look in culture, it’s precisely the same.”
http://tinyurl.com/c9bnq

AND THEN, THE FIRST DOSE OF HUMAN REALITY FROM 2006:
6-7-06 Ph1A HepC Efficacy PR: Joseph Shan, Peregrine's dir. of clinical & regulatory affairs, "These first efficacy results in humans are particularly exciting because researchers did not expect to see much anti-viral activity after a single dose of drug, based on our experience in lethal animal disease models such as Lassa fever. Bavituximab demonstrated good anti-viral activity in these studies, but only after administration of multiple doses. Based on the results reported today, the drug's anti-viral potential may be even more promising in humans than the animal models suggest."